---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-009416"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2026-06-24T13:00:38+00:00"
generated_at: "2026-06-24T13:02:22.527146+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics cuts 17% of workforce, expects $10M annual savings; pre-sBLA meeting in Aug 2026

## Summary
- Workforce reduction of ~17% globally, expected to generate ~$10M annualized cost savings.
- One-time pre-tax charges of ~$3M for severance and termination costs, mostly in Q2 2026.
- Pre-sBLA meeting with FDA in August 2026 for ZYNLONTA in r/r DLBCL; sBLA submission planned for Q4 2026.
- LOTIS-7 trial data anticipated by end of 2026; cash runway at least into 2028.
- Reorganization driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies.

## SEC filing metadata
- accession: 0000950103-26-009416
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2026-06-24T13:00:38+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/0000950103-26-009416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-009416
- JSON: https://secwatch.observer/filing/0000950103-26-009416.json
- Plain text: https://secwatch.observer/filing/0000950103-26-009416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.